期刊
INNOVATION
卷 1, 期 3, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xinn.2020.100066
关键词
N6-methyladenosine; cancer; RNA methylation; therapy
资金
- Shanghai Hospital Development Center [SHDC12015116]
- Fundamental Research Funds for the Central Universities [22120180607]
- National Natural Science Foundation of China [81802256]
- Science and Technology Commission of Shanghai Municipality [15411968400, 14411962600]
- Shanghai Pujiang Program [15PJD034]
- Shanghai Municipal Education Commission [18CG19]
- Shanghai Education Development Foundation [18CG19]
- Shanghai Pulmonary Hospital [FKYQ1907]
- Shanghai Rising-Star Program [20QA1408300]
N-6-Methyladenosine (m(6)A) RNA modification brings a new dawn for RNA modification researches in recent years. This posttranscriptional RNA modification is dynamic and reversible, and is regulated by methylases (writers), demethylases (erasers), and proteins that preferentially recognize m(6)A modifications (readers). The change of RNA m(6)A modification regulates RNA metabolism in eucaryon, including translation, splicing, exporting, decay, and processing. Thereby the dysregulation of m(6)A may lead to tumorigenesis and progression. Given the tumorigenic role of abnormal m(6)A expression, m(6)A regulators may function as potential clinical therapeutic targets for cancers. In this review, we emphasize on the underlying mechanisms of m(6)A modifications in tumorigenesis and further introduce the potential m(6)A regulators-associated therapeutic targets for tumor therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据